The margins have healed. The stock is up 63% from its low — so what is left to prove?
Third-quarter adjusted EPS of $4.69 beat the ~$4.12–$4.14 consensus and full-year guidance moved up to at least $20.50 — yet revenue is shrinking (−0.4%) because UnitedHealth is deliberately shedding Medicare Advantage lives. The market has already re-rated the recovery from ~14x to ~20x earnings. Is 2026’s margin repair a durable base to compound from, or a harvest that is already in the price? Six analyst lenses, three scenarios, four time horizons.
Gray line = UNH’s actual path from its Nov ’24 high ($631) through the Aug 1 ’25 close low ($235), the Mar 27 ’26 52-week low ($256) and the Jul 16 ’26 high ($462) to $417.00 today; it is built only from dated, sourced closes (no invented intermediate months), so the window is 23 months, not a full 24. Colored paths = synthesized scenario midpoints forward (price = same-year adjusted EPS × exit multiple), probability-weighted bear 30% · base 45% · bull 25% — tilted to the bear side because a DOJ probe and a policy-funding gap are unresolved. Open circle = Street 12-month consensus $477 (26 analysts, range $380–$529). Axis starts at $200, not zero.
Re-weight the scenarios
Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.
Six analyst lenses, six answers
The same Q3 print supports a $315 or a $490 stock depending on which framework you trust. Each lens below is a synthesized expert perspective with its own 12-month target. Panel mean: $433 (+4%) vs. a $477 Street consensus.
The Re-Compounder
Earnings power is rebasing up from a $20.50 floor. Q3 adjusted EPS grew 61%, Optum Health earned $735M vs $41M, and management called the low end of its 13–16% growth target a “reasonable starting point” for 2027 — above where consensus sits. Medicare Advantage margins are tracking the top of the 2–4% range.
The Cash Counter
$22.8B of trailing free cash flow is a ~6.1% yield on a $374B market cap, with $8.2B of dividends paid over the last twelve months and $5.0B of buybacks year-to-date. Debt-to-capital is 41.7% and heading toward 40%. The floor is cash, not hope — but ~$5.8B of the cash flow came from growth in claims reserves, which is timing.
The Shrinking Franchise
The repair was bought with scale: revenue −0.4%, Optum Health revenue −10%, plan exits that touch roughly 1M seniors across UnitedHealth and Humana, and a drop in members in 4-star-plus plans from 81% to 68%. DOJ civil and criminal probes remain open, and Optum Health guides to a “meaningfully negative” Q4. A re-rated 20x multiple leaves no room for a stumble.
The Integrated Stack
No peer pairs 48.3M insured members with a pharmacy-benefit arm where more than half of covered lives are now external, retention is in the high 90s, and specialty volumes grew 2.6% while overall volumes fell 5%. Optum Health reaches ~20M patients, ~4M in fully accountable relationships. The moat is the stack; the risk is that its profits depend on government payment rules.
The Tape Reader
Price sits above both the 50-day ($387.80) and 200-day ($360.27) averages, with RSI near 69 — strong, bordering on stretched. The stock is 63% off its March low but ~10% below the July high ($461.62), and 20.3x current-year EPS is mid-range against 17.4x–24.2x at the year-ends of 2021–25. A retest of the July high is the technical base case; a close above it opens the path.
The Policy Strategist
CMS finalized a 2.48% Medicare Advantage rate rise for 2027 (vs. 0.09% proposed) — a relief, but insurers still cite a gap versus medical cost trend. Government projections see ~34M MA enrollees, ~6% fewer than today, and management calls 2026 a trough year for Medicaid margins. A hot September CPI and a ~5.2% 10-year argue against multiple expansion even as healthcare draws defensive flows.
Wall Street 12-month price targets
What the sell-side expects over the next year. Bars are sorted low to high; the dashed line is today’s $417.00 — eight of the nine targets shown sit above it; only TD Cowen’s Hold ($402) sits below.
Sell-side 12-month targets — nine of the 26 analysts S&P Global polls (via StockAnalysis/TipRanks, Oct 9–21, 2026). Consensus mean $477.04, median $490; 22 of 26 rate the stock Buy or Strong Buy, 4 Hold, none Sell. Targets cluster tightly ($402–$526, eight of nine Buy) even after the stock’s 63% rebound, and several desks trimmed (Bernstein $512→$500, Raymond James $475→$450) while others raised (RBC $478→$498, J.P. Morgan $516→$524) after the Oct 13 print. The Street is at +14%; our blended 1-year view is roughly flat.
Where the chart leads
Synthesized scenario midpoints (mid-year). Returns shown vs. today’s $417.00. These are illustrative frameworks, not forecasts — the outcome hinges on whether 2027 earnings arrive and whether Medicare Advantage margins hold once the plan exits are behind it.
1 Year
Mid-20272 Years
Mid-20283 Years
Mid-20295 Years
Mid-2031▸ Bull case — show the assumptions & math
▸ Base case — show the assumptions & math
▸ Bear case — show the assumptions & math
Operating cash flow, capex, free cash flow & debt ($B)
Where the money actually goes. At $450B of revenue, plotting revenue would flatten every other bar, so operating cash flow stands in for it. The bull and bear theses both live in the gap between these four bars.
Cash flow fell from $29.1B (2023) to $19.7B (2025) as medical costs ran hot, then rebounded to $26.2B over the twelve months to September 2026; free cash flow went $25.7B → $16.1B → $22.8B. Capex is steady at ~$3.4–3.6B, so the swing is all operating. The bear’s caveat: ~$5.8B of the trailing figure is growth in unpaid-claims reserves (cash held for bills not yet paid), so it is partly timing. Total debt peaked at $83.0B at year-end 2025 and is $74.3B now — about 3.3 years of free cash flow — with debt-to-capital at 41.7%. Revenue for reference: $371.6B (2023), $400.3B (2024), $448.0B (2025), ~$448.7B consensus for 2026. Valuation snapshot (Oct 21): EV/EBITDA 14.6x, P/S 0.83x, P/FCF 16.4x, PEG 1.29. Source: S&P Global Market Intelligence via StockAnalysis; the company’s Q3 release.
EPS path underpinning the targets ($)
Each scenario price is an EPS estimate times an exit multiple. This is the earnings ladder the base case is built on — note it is still below the 2024 peak even in 2027.
Adjusted (non-GAAP) EPS: $27.66 (2024) and $16.35 (2025) reported; $20.51 (2026E) and $23.23 (2027E) are Street consensus, with 2026 management guidance “at least $20.50.” The lighter 2028E–2031E bars are our base-case extrapolation at +12%/yr — not consensus. Base-case 2031 EPS of ~$36.6 at ~17.5x ≈ the $640 five-year target. Valuation: 20.3x 2026E adjusted EPS (18.4x next-twelve-months; 23.8x trailing GAAP), versus 17.4x–24.2x at the year-ends of 2021–25. Peers on forward earnings: Cigna ~8.3x and CVS ~10.7x (Yahoo, Oct 14); Humana ~24.9x on normalized earnings (Morningstar, Oct 20) — so UNH trades at a premium to the insurers and in line with the other Medicare-recovery story. One aggregator shows 2024 adjusted EPS at $27.14; we use $27.66, which two sources agree on.
The business is shrinking — and earning more
Q3 FY26, year-over-year. Read the revenue lines against the profit lines: that disconnect is the whole thesis — and the whole debate.
Revenue lines (olive, plus Optum Rx earnings) are steady-to-shrinking: consolidated revenue $112.7B vs $113.2B, UnitedHealthcare $86.3B vs $87.1B, Optum Health $22.9B (−10%, fewer value-based patients in some markets). The profit lines (clay) are rebounding off a depressed Q3 2025: earnings from operations $6.6B vs $4.3B, UnitedHealthcare $2.8B vs $1.8B, adjusted EPS $4.69 vs $2.92. Optum Health operating earnings of $735M vs $41M (+1,693%, bar truncated at the axis break) come off a near-zero base — the percentage is arithmetic, the direction is the point. Sources: company Q3 2026 release (Oct 13) and call.
Bull vs. Bear
The entire valuation argument compresses into one disagreement: is the 2026 margin repair the new base, or the high-water mark of a harvest?
▲ THE BULL CASE
- The earnings inflection is real. Q3 adjusted EPS $4.69 vs $2.92; earnings from operations +53%; medical care ratio 88.4% vs 89.9%; operating cost ratio 12.8% vs 13.5%.
- Guidance keeps stepping up. The 2026 adjusted EPS outlook is now at least $20.50, versus an initial January outlook above $17.75.
- 2027 is framed as a growth year. The CFO called the low end of 13–16% a “reasonable starting point,” and said consensus may understate it; full 2027 guidance comes before year-end.
- Optum is healing. Optum Health earned $735M vs $41M with a 6–8% margin target by 2028; Optum Rx has over half its lives outside UnitedHealthcare and retention in the high 90s.
- A cash machine. $22.8B trailing free cash flow (~6.1% yield), $8.2B of dividends over twelve months with 16 years of dividend growth, $5.0B of buybacks year-to-date.
- Not stretched against its own history. 20.3x 2026E and 18.0x 2027E adjusted EPS vs. a 17.4x–24.2x year-end range over 2021–25; Street consensus sees +14%.
▼ THE BEAR CASE
- The top line is shrinking. Revenue −0.4%, UnitedHealthcare −0.9%, Optum Health −10%; industry Medicare Advantage enrollment is projected ~6% lower in 2027.
- The repair is a harvest. UnitedHealth and Humana are ending plans covering nearly 1M seniors; UNH’s members in 4-star-plus plans fall from 81% to 68% for 2027, which pressures bonus payments.
- The legal overhang is open. Criminal and civil DOJ probes into Medicare billing were still described as unresolved in the latest coverage found; a Senate report alleged upcoding; Berkshire has exited its position.
- Policy still lags cost trend. The 2027 final rate (+2.48%) helped, but peers cite a persistent gap to trend; management calls 2026 the Medicaid margin trough and flags persistent medical trend and pressured funding for 2027.
- The next two prints are a test. Optum Health is guided to a “meaningfully negative” Q4 on investments and seasonality, and “at least $20.50” leaves little visible cushion.
- The re-rating is largely done. The stock is up 63% from its low at ~20x vs. Cigna ~8x and CVS ~11x forward; further upside needs earnings to beat a consensus already near the low end of the 13–16% range.
Risk map — likelihood × impact
Where each risk sits over the next 3–5 years, not just how big it is. The hot upper-right corner — likely and high-impact — is the one that matters; most of UnitedHealth’s legal and structural risks sit one row down, in “possible.” Placements are our judgment.
- Stars erosion
- Optum drag
- Cost-trend gap
- De-rating
- Medicaid funding
- DOJ outcome
- PBM reform
- Cyber shock
- MA overhaul
Cost-trend gap
Medical cost trend outruns Medicare and Medicaid payment rates again; the 88.4% medical care ratio slips back toward 90% and the $20.50 floor stops being a floor.
Stars erosion
Members in 4-star-plus plans fall from 81% to 68% for 2027; fewer quality-bonus dollars arrive in 2028 payments even as margins improve.
Optum drag
Management guides a “meaningfully negative” Optum Health Q4 and multi-year Optum Insight investment; the Optum recovery arrives later than the headline implies.
DOJ outcome
Civil and criminal probes into Medicare billing conclude with penalties or forced changes to risk-adjustment practices in the company’s largest revenue stream.
PBM reform
Federal drug-pricing or rebate rules compress Optum Rx, which earned $1.7B of operating profit in Q3 alone.
Cyber shock
A repeat of the 2024 Change Healthcare-style attack disrupts claims flow across the network — low odds, but it reprices the stock and invites regulation.
MA overhaul
A structural change to Medicare Advantage risk adjustment or benchmarks resets the economics of the segment that produces the most revenue.
De-rating
Hot inflation and a ~5.2% 10-year pull the multiple from 20x toward the mid-teens even if earnings deliver.
Medicaid funding
State funding stays uneven and 2026 proves not to be the trough; Medicaid margins stay below the rate-adequate level management expects by 2028.
The jargon, decoded
Hover the dotted terms in the metrics, or scan the desk’s working definitions here.
- Medical care ratio (MCR)
- The share of premium revenue paid out as medical claims. 88.4% means ~$88 of every $100 goes to care and ~$12 is left for admin and profit. Lower is better.
- Medicare Advantage (MA)
- Private plans that deliver Medicare benefits and are paid a per-member rate by the government. UnitedHealth’s largest revenue stream.
- Star ratings
- CMS quality scores. Plans rated 4 stars or higher earn bonus payments, so the share of members in those plans moves profit.
- Adjusted EPS
- Earnings per share excluding one-time items. This report’s targets use adjusted EPS; trailing GAAP EPS is lower.
- Free cash flow
- Operating cash flow minus capex — the fuel for dividends and buybacks. ~$22.8B trailing.
- FCF yield
- Free cash flow ÷ market cap. ~6.1% here: about $6 of cash a year per $100 of stock.
- PBM (Optum Rx)
- A pharmacy benefit manager negotiates drug prices and rebates for employers and insurers. Optum Rx is UnitedHealth’s PBM.
- Value-based care
- Paying providers for keeping patients healthy rather than per visit. Optum Health earns on it when costs come in under the premium.
- Exit multiple & prob-weighted
- The P/E assumed at the end of a forecast, times EPS, gives a target price. Prob-weighted sums each scenario’s price times its probability.